These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 37335635)

  • 1. Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy.
    Hassan F; Saleem A; Samuel SS; Sarfraz Z; Sarfraz A; Sarfraz M; Kc M
    Medicine (Baltimore); 2023 Jun; 102(23):e33978. PubMed ID: 37335635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
    Akhtar SMM; Ali A; Khan MS; Khan V; Fareed A; Saleem SZ; Mumtaz M; Ahsan MN; Iqbal S; Asghar MS
    Int J Gynaecol Obstet; 2024 Sep; 166(3):969-983. PubMed ID: 38563867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
    Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
    Rahman UA; Kashif TB; Usman M; Rana M; Hasanain M; Anjum MU; Cheema HA; Jaffar H; Bhattarai P
    Medicine (Baltimore); 2023 Dec; 102(50):e36592. PubMed ID: 38115258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review.
    Menown SJ; Tello JA
    Adv Ther; 2021 Oct; 38(10):5025-5045. PubMed ID: 34514552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of omega-3 supplements on vasomotor symptoms in menopausal women: A systematic review and meta-analysis.
    Mohammady M; Janani L; Jahanfar S; Mousavi MS
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():295-302. PubMed ID: 30056356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
    Lederman S; Ottery FD; Cano A; Santoro N; Shapiro M; Stute P; Thurston RC; English M; Franklin C; Lee M; Neal-Perry G
    Lancet; 2023 Apr; 401(10382):1091-1102. PubMed ID: 36924778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause.
    Cieri-Hutcherson NE; Marji EK; Hutcherson TC
    Menopause; 2024 Apr; 31(4):342-354. PubMed ID: 38471077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
    Tahara A; Takamatsu H; Ohtake A; Tanaka-Amino K; Kaku S
    Eur J Pharmacol; 2021 Aug; 905():174207. PubMed ID: 34048742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis.
    Chavez MP; Pasqualotto E; Ferreira ROM; Hohl A; de Moraes FCA; Schmidt PHS; Rodrigues ALSO; de Sa JR
    Climacteric; 2024 Jun; 27(3):245-254. PubMed ID: 38619017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants.
    Elhusein AM; Fadlalmola HA; Abedelwahed HH; Elshaikh AA; Banaga AE; Alrahman MHF; Abdelgadim NH; Mohammed IH; Abdalla AAA; Abdalla FAM; Abd Allah EM; Abbas NI; Alhujaili AD; Almkiy EA; Idress EA; Awadalkareem EM; Abdeldafie SY; Balusamy P; Mohamed RA; Aloufi RSM; Habiballa M; Abdelmalik MA; Alhejaili MM; Ibrahim IA; Masaad HK
    Afr J Reprod Health; 2024 Mar; 28(3):99-113. PubMed ID: 38583073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
    Depypere H; Lademacher C; Siddiqui E; Fraser GL
    Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119
    [No Abstract]   [Full Text] [Related]  

  • 13. Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause.
    Roberts MZ; Andrus MR
    Expert Opin Pharmacother; 2024 Jun; 25(9):1131-1136. PubMed ID: 38953697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
    Morga A; Ajmera M; Gao E; Patterson-Lomba O; Zhao A; Mancuso S; Siddiqui E; Kagan R
    Menopause; 2024 Jan; 31(1):68-76. PubMed ID: 38016166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
    Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
    Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies.
    Zhu D; Chung HF; Dobson AJ; Pandeya N; Anderson DJ; Kuh D; Hardy R; Brunner EJ; Avis NE; Gold EB; El Khoudary SR; Crawford SL; Mishra GD
    Am J Obstet Gynecol; 2020 Dec; 223(6):898.e1-898.e16. PubMed ID: 32585222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis.
    Shan D; Zou L; Liu X; Shen Y; Cai Y; Zhang J
    Am J Obstet Gynecol; 2020 Jun; 222(6):564-579.e12. PubMed ID: 31870736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of paroxetine for the treatment of vasomotor symptoms.
    Slaton RM; Champion MN; Palmore KB
    J Pharm Pract; 2015 Jun; 28(3):266-74. PubMed ID: 25107421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis.
    Franco OH; Chowdhury R; Troup J; Voortman T; Kunutsor S; Kavousi M; Oliver-Williams C; Muka T
    JAMA; 2016 Jun; 315(23):2554-63. PubMed ID: 27327802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
    Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.